Yuval Patel, MD
Gastroenterology · Ponte Vedra, FLNPI 1609106210
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Madrigal Pharmaceuticals at 40.6% of the total. 2025 is the largest year on record at $21,936, 5.9 times the $3,740 reported in 2020. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $314.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$19K
- Novo Nordisk$19K
- Intercept Pharmaceuticals, Inc.$7K
- AbbVie$413
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
- Pfizer$235
- plus $1K from 17 others
Across 1 payment — averaging $61,817 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$62K
What the payments were for
- Consulting fees$21,02945%
- Speaking & faculty fees$21,06345%
- Travel & lodging$1,5953%
- Food & beverage$3,4857%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 23 | $19,174 |
| Novo Nordisk | 9 | $19,116 |
| Intercept Pharmaceuticals, Inc. | 3 | $6,615 |
| AbbVie | 21 | $413 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $272 |
| Pfizer | 16 | $235 |
| Lilly USA, LLC | 8 | $162 |
| Sanofi | 7 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $137 |
| Regeneron Healthcare Solutions, Inc. | 7 | $134 |
| Aimmune Therapeutics, Inc. | 6 | $115 |
| Johnson & Johnson | 7 | $115 |
| Gilead | 4 | $93 |
| QOL Medical, LLC | 3 | $86 |
| Alnylam Pharmaceuticals Inc. | 3 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $73 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Evoke Pharma, Inc. | 1 | $42 |
| Ardelyx, Inc. | 2 | $38 |
| Merck | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,172 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 24 | $23,165 |
| CreonLipase/Protease/Amylase | 12 | $17,561 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 46 | $6,597 |
| Omeprazole | 150 | $2,307 |
| Colestipol Hcl | 17 | $1,053 |
| Esomeprazole Magnesium | 19 | $861 |
| Pantoprazole Sodium | 39 | $695 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $358 |
| Ondansetron Hcl | 11 | $233 |
| Dicyclomine Hcl | 15 | $184 |
| Sucralfate | 12 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $413 | $40,72636 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $272 | $6,59746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Ponte Vedra
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.